Strikingly, the approvals of [131I]I-metuximab-F(ab’)2 (Licartin®) by the Chinese FDA for the treatment of metastatic refractory hepatocellular carcinoma, [177Lu]Lu-DOTATATE (Lutathera®) by the EMA and FDA for the treatment of metastatic and inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NET), and more recently [177Lu]Lu-PSMA-617 (PluvitoTM) for the treatment of PSMA-positive metastatic castration-resistant metastatic prostate cancer have played a pivotal role. This evidence concerns the gene FOLH1 and digestive system neuroendocrine tumor, grade 1/2.